[Timolol topical ophthalmic combination]
- PMID: 15279411
[Timolol topical ophthalmic combination]
Abstract
The primary standard therapy in patients with open-angle glaucoma and ocular hypertension is carried out by means of monotherapy with synthetic prostaglandin analogues. Most of the glaucoma patients need more than one medication for adequate intraocular pressure control. Timolol represents the basic component of these combinations. Timolol topical ophthalmic combinations with dorzolamide (Cosopt), pilocarpine, latanoprost (Xalacom), travoprost and unoprostone are thoroughly described. Most antiglaucoma medications achieve on one side directly baroprotection by decreasing intraocular pressure and on the other side they produce indirectly vasoprotection, that is secondary to intraocular pressure lowering. The Cosopt, due to its Dorzolamide component, makes an exception since it produces directly both baroprotection by aqueous humor flow suppression and vasoprotection by increasing the blood flow within the retina, choroid, optic nerve head and retrobulbar area. Given these considerations as well as the fact that the ocular hypotensive effect of both the Cosopt and the latanoprost are equally potent, a question seems reasonable according to accepted standard i.e. Cosopt or latanoprost as primary glaucoma therapy?
Similar articles
-
Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.Ophthalmology. 2008 Jul;115(7):1117-1122.e1. doi: 10.1016/j.ophtha.2007.10.004. Epub 2008 Feb 20. Ophthalmology. 2008. PMID: 18082886
-
Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure.Ophthalmology. 2004 Feb;111(2):276-82. doi: 10.1016/j.ophtha.2003.05.019. Ophthalmology. 2004. PMID: 15019375 Clinical Trial.
-
Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.J Glaucoma. 2010 Jun-Jul;19(5):331-5. doi: 10.1097/IJG.0b013e3181b4cab4. J Glaucoma. 2010. PMID: 19730119 Clinical Trial.
-
Latanoprost : an update of its use in glaucoma and ocular hypertension.Drugs Aging. 2003;20(8):597-630. doi: 10.2165/00002512-200320080-00005. Drugs Aging. 2003. PMID: 12795627 Review.
-
The effect of latanoprost on circadian intraocular pressure.Surv Ophthalmol. 2002 Aug;47 Suppl 1:S90-6. doi: 10.1016/s0039-6257(02)00296-5. Surv Ophthalmol. 2002. PMID: 12204704 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical